Blockade of A2aR on mice demonstrated increased proliferative capacity and function of T cells, as well as enhanced immunologic memory [42]. Preliminary results from a phase I clinical trial evaluating the oral adenosine A2aR antagonist CPI-444 alone and in combination with atezolizumab for advanced...
Abstract CT119: CPI-444, an oral adenosine A2a receptor (A2aR) antagonist, demonstrates clinical activity in patients with advanced solid tumors. Cancer Res. 2017;77:CT119. 46. Antonioli L, Novitskiy SV, Sachsenmeier KF, et al. Switching off CD73: a way to boost the activity of ...
55..CCoonncclluuddiinnggRReemmaarrkkss IInntthhisisppaappeerrwweehhaavveeshshorotrltylyrerceaclalelldedthtehme majoarjotrectehcnhiqnuiqeuseasnadntdhethceurcruernrtenretsreeasrecahrcdhiredcitrieocntisoinns SiCn SreCseraersceha—rchw—ithwaitnh eaxnpelixcpitlifcoictufosctuosStCosSbCassebdasoend ...